Trial Profile

A Randomized, Double-Blind Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emraclidine (Primary)
Indications Schizophrenia
Focus Therapeutic Use
Sponsors Cerevel Therapeutics

Most Recent Events

19 Dec 2022 Results presented in a Cerevel Therapeutics Media Release.
13 Dec 2022 Status changed from active, no longer recruiting to completed.
11 Oct 2022 Planned End Date changed from 17 Oct 2022 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com